TRUMY (Terumo) Current Accrued Expense : $0 Mil (As of Mar. 2025)

View and export this data going back to 2008. Start your Free Trial

What is Terumo Current Accrued Expense?

Terumo's Current Accrued Expense for the quarter that ended in Mar. 2025 was $0 Mil.

Terumo Current Accrued Expense Historical Data

The historical data trend for Terumo's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Terumo Current Accrued Expense Chart

Terumo Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Current Accrued Expense

Get a 7-Day Free Trial

Terumo Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Terumo Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Terumo Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Terumo's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Terumo Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Terumo Corp (OTCPK:TRUMY) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

TRUMF:USA 4543:Japan TUO0:Germany

Address

2-44-1 Hatagaya, Shibuya-ku, Tokyo, JPN, 151-0072

Website

https://www.terumo.com

Started as a clinical thermometer producer in Japan in 1921, Terumo is a comprehensive medical device player with a diversified global revenue. Its product portfolio includes prefilled syringes, insulin patch pumps, neurovascular or cardiac vascular interventional devices, and blood processing systems. As of 2024, the cardiac and vascular business is the largest segment, contributing over 60% of its total revenue. Geographically, North America is the largest region, with 36% of Terumo's revenue.